125 related articles for article (PubMed ID: 11266733)
1. Inhibition of in vitro donor-specific proliferative and cytotoxic T cell responses in chimeric CD40 ligand-deficient bone marrow transplant recipients treated perioperatively with CTLA4-Ig.
Woodward JE; Schaefer AT; Zottola LB; Stazer JK; Logar AJ; Peach R; Rao AS
Transplant Proc; 2001; 33(1-2):113-4. PubMed ID: 11266733
[No Abstract] [Full Text] [Related]
2. Blockade of the CD28/B7 pathway is required for the establishment of donor cell chimerism in CD40 ligand-deficient recipients.
Woodward JE; Zottola LB; Schaefer AT; Logar AJ; Stazer JK; Daskivich T; Peach R; Rao AS
Transplant Proc; 2001; 33(1-2):115. PubMed ID: 11266734
[No Abstract] [Full Text] [Related]
3. Flt3-L augments the engraftment of donor-derived bone marrow cells when combined with sublethal irradiation and costimulatory (CD28/B7 and CD40/CD40L) blockade.
Woodward JE; Salam A; Logar AJ; Schaefer AT; Rao AS
Cell Transplant; 2002; 11(2):147-59. PubMed ID: 12099638
[TBL] [Abstract][Full Text] [Related]
4. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts.
Li S; Thanikachalam M; Pang M; Kawaharada N; Aitouche A; Pham SM
Ann Thorac Surg; 2001 Oct; 72(4):1306-10. PubMed ID: 11603451
[TBL] [Abstract][Full Text] [Related]
5. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
7. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death.
Wekerle T; Kurtz J; Sayegh M; Ito H; Wells A; Bensinger S; Shaffer J; Turka L; Sykes M
J Immunol; 2001 Feb; 166(4):2311-6. PubMed ID: 11160287
[TBL] [Abstract][Full Text] [Related]
8. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
Adams AB; Durham MM; Kean L; Shirasugi N; Ha J; Williams MA; Rees PA; Cheung MC; Mittelstaedt S; Bingaman AW; Archer DR; Pearson TC; Waller EK; Larsen CP
J Immunol; 2001 Jul; 167(2):1103-11. PubMed ID: 11441122
[TBL] [Abstract][Full Text] [Related]
9. Transplantation and the CD28/CTLA4/B7 pathway.
Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
[No Abstract] [Full Text] [Related]
10. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig.
Zhou P; Szot G; Guo Z; Kim O; He G; Wang J; Grusby M; Newell K; Thistlethwaite J; Bluestone J; Alegre M
Transplant Proc; 2001; 33(1-2):214-6. PubMed ID: 11266784
[No Abstract] [Full Text] [Related]
11. Transplantation of anergic histoincompatible bone marrow cells.
de Carvalho Bittencourt M; Tiberghien P; Saas P
N Engl J Med; 1999 Sep; 341(14):1081-2. PubMed ID: 10507928
[No Abstract] [Full Text] [Related]
12. Transplantation of anergic histoincompatible bone marrow allografts.
Guinan EC; Boussiotis VA; Neuberg D; Brennan LL; Hirano N; Nadler LM; Gribben JG
N Engl J Med; 1999 Jun; 340(22):1704-14. PubMed ID: 10352162
[TBL] [Abstract][Full Text] [Related]
13. Prolonged allograft survival following ex vivo blockade of costimulatory signals B7-1/2 and CD40.
Steurer W; Oellinger R; Perwanger F; Brandacher G; Obrist P; Klima G; Margreiter R
Transplant Proc; 2001; 33(1-2):274-5. PubMed ID: 11266816
[No Abstract] [Full Text] [Related]
14. Anti-CD40 therapy extends renal allograft survival in rhesus macaques.
Pearson TC; Trambley J; Odom K; Anderson DC; Cowan S; Bray R; Lin A; Hollenbaugh D; Aruffo A; Siadak AW; Strobert E; Hennigar R; Larsen CP
Transplantation; 2002 Oct; 74(7):933-40. PubMed ID: 12394833
[TBL] [Abstract][Full Text] [Related]
15. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
16. Tolerating differences.
Sikorski R; Peters R
Science; 1999 Jul; 285(5426):357-8. PubMed ID: 10438301
[No Abstract] [Full Text] [Related]
17. Mechanisms of donor-specific tolerance in a skin transplantation model.
van Pel M; Vingerhoed J; de Vries-van der Zwan A; van der Pol MA; Boog CJ
Transplant Proc; 2001; 33(1-2):152-3. PubMed ID: 11266754
[No Abstract] [Full Text] [Related]
18. Inhibition of human anti-pig T cell response by anti-CD2, anti-CD40L, and CTLA4-Ig: a comparative study.
Xu Y; Ryan D; Wu C; Bazin H; Latinne D; White-Scharf ME; Thall AD
Transplant Proc; 2000 Aug; 32(5):926. PubMed ID: 10936275
[No Abstract] [Full Text] [Related]
19. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.
Wekerle T; Kurtz J; Ito H; Ronquillo JV; Dong V; Zhao G; Shaffer J; Sayegh MH; Sykes M
Nat Med; 2000 Apr; 6(4):464-9. PubMed ID: 10742157
[TBL] [Abstract][Full Text] [Related]
20. CTLA4-Ig inhibits rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with increased lymphocyte apoptosis.
Li W; Lu L; Wang Z; Wang L; Thomson A; Fung J; Qian S
Transplant Proc; 2001; 33(1-2):246-7. PubMed ID: 11266801
[No Abstract] [Full Text] [Related]
[Next] [New Search]
